What You Should Know:
– Goldman Sachs Asset Management has announced the closing of its first-ever life sciences fund, West Street Life Sciences I, surpassing its target with $650 million in commitments.
– This marks a…
Continue Reading
Penn Medicine’s iStar emerges as a game-changing AI tool, developed by Perelman School of Medicine experts. This revolutionary application, short for Inferring Super-Resolution Tissue Architecture, presents a paradigm shift in oncology diagnostics. iStar delves…
Continue Reading
Chaim Linhart, Chaim, Co-founder and CTO at Ibex Medical Analytics
Artificial intelligence (AI) technology is set to transform the field of diagnostics, similar to how X-rays and genetic tests revolutionized healthcare in the past. Reshaping…
Continue Reading
Mass General Brigham foresees a groundbreaking AI revolution in healthcare. Experts anticipate AI’s impact across specialties: refining neurosurgery precision, boosting radiology diagnostics, deploying patient chatbots, and smarter AI-driven care. Driven by leaders like Dr….
Continue Reading
Diagnostics company LumiraDx announced it signed an agreement to sell its point-of-care technology to pharma giant Roche for $295 million, with an additional payment of $55 million to fund the platform until the acquisition…
Continue Reading
What You Should Know:
– Intelligent Scopes Corp, a subsidiary of Claritas HealthTech Ltd., and Mayo Clinic have joined forces to develop cutting-edge artificial intelligence (AI) solutions for bladder cancer diagnosis and treatment.
– The goal…
Continue Reading
AI’s synergy with radiology reshapes healthcare by enhancing diagnostics, streamlining workflows, and amplifying precision. Evolving from early skepticism, AI, especially deep learning and radiomics, redefines diagnostics. AI’s integration spans the patient journey, optimizing processes…
Continue Reading
Lunit’s acquisition of Volpara at AUD 1.15 per share marks a pivotal move in cancer diagnostics. The Scheme Implementation Agreement targets Volpara’s AI-enabled solutions, expanding Lunit’s global presence. Volpara’s 100 million mammogram images promise…
Continue Reading
During the global pandemic, the world saw firsthand how essential clinical trials were in developing medicines to improve health and extend human life. Clinical research sites, including academic medical centers (AMC), non-AMCs and professional…
Continue Reading
Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform…
Continue Reading
